Research Topics
| L S MarksSummaryAffiliation: University of California Country: USA Publications
| Collaborators
|
Detail Information
Publications
Rapid efficacy of the highly selective α(1A)-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studiesLeonard S Marks
University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, CA, USA
J Urol 189:S122-8. 2013..We evaluated the efficacy and safety of silodosin for treatment of benign prostatic hyperplasia symptoms in 2 randomized, placebo controlled, phase 3 studies...
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendationsLeonard S Marks
Department of Urology, School of Medicine, University of California Los Angeles, Los Angeles, CA, USA
J Urol 176:868-74. 2006....- Prostatic tissue testosterone and dihydrotestosterone in African-American and white menLeonard S Marks
Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
Urology 68:337-41. 2006..To compare tissue androgen levels in the prostate gland of African-American and white men, looking for a possible explanation of the increased incidence of cancer in the former... - Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia diseaseLeonard S Marks
Department of Urology, Geffen School of Medicine at UCLA, Urological Sciences Research Foundation, 3831 Hughes Avenue, Culver City, CA 90232, USA
Curr Urol Rep 7:293-303. 2006..Thus, we now can identify men with an enlarged prostate at risk for BPH disease who may be candidates for preventive therapy with 5ARIs, regardless of urinary symptoms or bother... - Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implantLeonard S Marks
Urological Sciences Research Foundation, Culver City, California 90232, USA
Urology 62:36-42. 2003..Thus, a long-term strategy-permitting increased patient freedom and decreased dependence on a fixed injection schedule-has for the first time become possible with the Viadur implant in men requiring hormone therapy for prostate cancer... - Prevention of benign prostatic hyperplasia diseaseLeonard S Marks
Urological Sciences Research Foundation and Department of Urology, Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90232, USA
J Urol 176:1299-306. 2006..We reviewed the evidence that benign prostatic hyperplasia is a progressive condition and men at risk for benign prostatic hyperplasia disease can be identified, treated and protected to a meaningful extent regardless of symptom status... - Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trialLeonard S Marks
Department of Urology, Geffen School of Medicine, University of California, Los Angeles, USA
JAMA 296:2351-61. 2006..Prostate safety is a primary concern when aging men receive testosterone replacement therapy (TRT), but little information is available regarding the effects of TRT on prostate tissue in men... - PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsyLeonard S Marks
Urological Sciences Research Foundation, Los Angeles, California 90232, USA
Urology 69:532-5. 2007..We evaluated the potential utility of the investigational prostate cancer gene 3 (PCA3) urine assay to predict the repeat biopsy outcome... - The effect of dutasteride on the peripheral and transition zones of the prostate and the value of the transition zone index in predicting treatment responseLeonard S Marks
Department of Urology, University of California, Los Angeles School of Medicine and Urological Sciences Research Foundation, Los Angeles, California 90232, USA
J Urol 177:1408-13. 2007..We determined the effects of dutasteride on transition and peripheral zone volume, and the clinical value of the transition zone index in men with benign prostatic hyperplasia... - Prostate tissue androgens: history and current clinical relevanceLeonard S Marks
Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
Urology 72:247-54. 2008..Determination of prostate tissue androgens may soon transition from research tool to clinical test... - Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studiesLeonard S Marks
University of California at Los Angeles and Urological Sciences Research Foundation, Los Angeles, California, USA
J Urol 181:2634-40. 2009..We evaluated the efficacy and safety of silodosin for treatment of benign prostatic hyperplasia symptoms in 2 randomized, placebo controlled, phase 3 studies... - The role of prostate needle biopsy in evaluation of chemopreventive agentsL S Marks
Urological Sciences Research Foundation and Department of Urology, UCLA School of Medicine, Los Angeles, California, USA
Urology 57:191-3. 2001..The serial biopsy approach may be especially valuable in "watchful waiting" cohorts... - Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgensL S Marks
Urological Sciences Research Foundation, Culver City, California, USA
Urology 57:999-1005. 2001..The SPHB-induced suppression of prostatic DHT levels, modest but significant in a randomized trial, lends an element of support to the hypothesis that inhibition of the enzyme 5-alpha reductase is a mechanism of action of this substance... - Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agentsA W Partin
James Buchanan Brady Urological Institute, The Johns Hopkins School of Medicine, Department of Urology, Baltimore, Maryland, USA
Urology 57:132-6. 2001..This update will focus on a critical evaluation of prostate-specific antigen (PSA), percentage of free PSA, and human glandular kallikrein-2 (hK2) and how they may be used or misused for chemoprevention studies... - Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasiaMichael Marberger
Department of Urology, University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
J Clin Endocrinol Metab 91:1323-8. 2006..Although benign prostatic hyperplasia (BPH) is an androgen-dependent disorder, little is known regarding the influence of serum testosterone levels on sexual or prostate function or clinical response to dutasteride... - Free prostate-specific antigen in serum is becoming more complexStephen D Mikolajczyk
Hybritech Incorporated, San Diego, California 92121, USA
Urology 59:797-802. 2002 - PCA3: a molecular urine assay for predicting prostate biopsy outcomeIna L Deras
Gen Probe, Inc, San Diego, California 92121, USA
J Urol 179:1587-92. 2008..We further characterized PCA3 performance in different groups of men and determined whether the PCA3 score could synergize with other clinical information to predict biopsy outcome... - Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanismRobert W Veltri
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Urology 60:617-22. 2002..Thus, a possible molecular basis for tissue changes and therapeutic effect of the compound is suggested... - Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate diseaseHarry J Linton
Hybritech Incorporated, a subsidiary of Beckman Coulter, Inc, 7330 Carroll Road, San Diego, CA 92121, USA
Clin Chem 49:253-9. 2003..BPSA has a wide distribution of concentrations in the serum and may provide clinical information for the study of men with BPH... - Treatment of men with minimally symptomatic benign prostatic hyperplasia--PRO: the argument in favorLeonard S Marks
Urology 62:781-3. 2003 - Alterations in nuclear structure and expression of proPSA predict differences between native Japanese and Japanese-American prostate cancerRobert W Veltri
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
Urology 68:898-904. 2006..These preliminary observations indicate a basis for biologic and molecular alterations in the benign adjacent and malignant epithelium between these two groups... - Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasiaClaus G Roehrborn
Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390-9110, USA
Urology 63:709-15. 2004..Near-complete, long-term suppression of dihydrotestosterone (93% at 48 months) with dutasteride did not lead to an increase in adverse events compared with that reported in the 2-year period... - Prostate cancer in native Japanese and Japanese-American men: effects of dietary differences on prostatic tissueLeonard S Marks
Department of Urology, University of California, Los Angeles, Geffen School of Medicine, Los Angeles, California, USA
Urology 64:765-71. 2004..Differences in nuclear morphometry suggested the additional possibility of gene-nutrient interactions... - APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancerJack Groskopf
Gen Probe Incorporated, San Diego, CA 92121, USA
Clin Chem 52:1089-95. 2006..Prostate cancer gene 3 (PCA3) encodes a prostate-specific mRNA that has shown promise as a prostate cancer diagnostic tool. This report describes the characterization of a prototype quantitative PCA3-based test for whole urine... - First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasiaLeonard S Marks
Urological Sciences Research Foundation and Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, California 90232, USA
Urology 62:888-93. 2003.... - Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice settingMICHAEL P O'LEARY
Harvard Medical School, Brigham and Women s Hospital, Boston, MA 02115, USA
BJU Int 101:1531-5. 2008.... - PC-SPES: herbal formulation for prostate cancerLeonard S Marks
Urological Sciences Research Foundation, Culver City, California 90232, USA
Urology 60:369-75; discussion 376-7. 2002..PC-SPES is of great interest in men with androgen-independent CaP, an area in which future research should be primarily directed... - Cathepsin B expression in prostate cancer of native Japanese and Japanese-American patients: an immunohistochemical studyAkhouri A Sinha
Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, Minnesota 55455, USA
Anticancer Res 28:2271-7. 2008.... - Effects of untreated syphilis in the negro male, 1932 to 1972: a closure comes to the Tuskegee study, 2004Shamim M Baker
Urology 65:1259-62. 2005